JWATM214 / Eureka Therap, JW (Cayman) Therap - LARVOL DELTA

Innovent Biologics (02126) announces interim results, achieves revenue of RMB 86.815 million, and continues to make significant progress in commercialization of its leading product Benoda [Google translation] (new.qq.com) - "...Innovent Biologics-B (02126) released its interim results for the six months ended June 30, 2024. The group achieved revenue of 86.815 million yuan (RMB, the same below) during the period, which remained relatively stable year-on-year; gross profit of 43.745 million yuan, which remained relatively stable year-on-year; and R&D expenses of 151 million yuan...The announcement stated that the stable sales performance was due to the continued commercialization of the Group's CD19-targeted autologous CAR-T cell immunotherapy product, relma-cel....The Group has also initiated an investigator-initiated trial (IIT) of JWATM214 for the treatment of advanced hepatocellular carcinoma (HCC)."

Sales • Trial status • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma (PRNewswire) - "JW Therapeutics...announced the initiation of clinical study of JWATM214 in patients with advanced hepatocellular carcinoma (HCC) and the first patient infusion....This first-in-human study of JWATM214 aims to evaluate the safety and tolerability, determine the recommended phase 2 dose (RP2D), and evaluate the pharmacokinetic profile and preliminary efficacy of JWATM214 in adult patients with GPC-3-expressing advanced HCC."

Trial status • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor